+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bcl 2 Like Protein"

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 71 Pages
  • Global
From
Bcl-2-Like Protein 1 Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Bcl-2-Like Protein 1 Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • February 2023
  • 72 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Bcl 2 Like Protein market is a subset of the larger oncology drugs market. Bcl 2 Like Proteins are a family of proteins that regulate apoptosis, or programmed cell death, in cells. They are important in the treatment of cancer, as they can be used to induce apoptosis in cancer cells, while leaving healthy cells unharmed. Bcl 2 Like Proteins are also used in combination with other drugs to enhance the efficacy of cancer treatments. The Bcl 2 Like Protein market is highly competitive, with many companies developing and marketing these drugs. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more